Psoriatic arthritis: An assessment of clinical, biochemical and radiological features in a single-centre South African cohort by Maharaj, AB et al.
RESEARCH
630       June 2016, Vol. 106, No. 6
Although psoriatic arthritis (PsA) is a well-documented clinical 
entity,[1] epidemiological, clinical and radiological studies of 
South African (SA) patients are scarce. There are, in fact, no 
published data regarding the prevalence and incidence of PsA in 
the SA population. In 1973, Moll and Wright[1] defined PsA as an 
inflammatory arthritis associated with psoriasis in the absence 
of rheumatoid factor (RF), and it was not until 2006 that the 
ClASsification criteria for Psoriatic ARthritis (CASPAR) were 
introduced for the purpose of diagnosis.[2] The long-recognised 
Moll and Wright criteria[1] are widely accepted diagnostic criteria 
that divide PsA into five different types, based on the patterns 
of joint involvement: (i) polyarticular; (ii) distal interphalangeal 
(DIP); (iii) spondyloarthropathy; (iv) oligoarticular; and (v) 
arthritis mutilans.[1] There are some patients in the reported 
literature who presented with overlapping symptoms and therefore 
cannot be classified into a specific group.[1]
PsA is a heterogeneous disease associated with inflammatory 
arthritis, enthesopathies and new bone formation together with ero-
sive arthropathy.[3,4] The absence of RF is well documented in patients 
with PsA.[5] For many years, PsA was considered a less aggressive dis-
ease than rheumatoid arthritis; however, recent studies have revealed 
severe erosions and ankylosis in patients with PsA.[6-8] We examined 
the clinical, biochemical and radiological features of PsA in a cohort 
of 384 SA patients.
Objectives
To document the features of PsA in SA patients and determine the 




Our study, which was approved by the Pharma-Ethics Independent 
Research Committee of South Africa (Ref. No. 1309560), included 
384 consecutive patients diagnosed with PsA at the rheumatology 
clinic at Prince Mshiyeni Memorial Hospital (PMMH), Durban, SA, 
between January 2007 and December 2013. The duration of disease 
symptoms varied between patients. PsA was diagnosed by one of several 
consultants with a special interest in the disorder, and the diagnoses were 
based on the Moll and Wright criteria.[1] RF positivity is well documented 
in a small proportion of healthy individuals, and the prevalence increases 
with age.[9] Nevertheless, patients who were RF-positive were included 
in the study if they fulfilled the Moll and Wright diagnostic criteria.[1,10] 
Patients with rheumatoid arthritis, osteoarthritis or other mechanical 
joint disease, reactive arthritis, and other seronegative arthritides 
or crystal-associated arthropathy were excluded, as were those with 
evidence of collagen vascular disease. Patients with PsA with secondary 
mechanical arthropathies were included. All the patients in the study 
provided written informed consent to participate.
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Background. Although psoriatic arthritis (PsA) is a well-documented clinical entity, epidemiological, clinical and radiological studies of 
South African (SA) patients are scarce.
Objectives. To assess clinical, biochemical and radiological features in a single-centre SA cohort.
Methods. We conducted a prospective assessment of the clinical, biochemical and radiological features of 384 consecutive patients with 
PsA seen at the rheumatology clinic at Prince Mshiyeni Memorial Hospital, Durban, SA, between January 2007 and December 2013. 
Patients were assessed at enrolment and 6 months after enrolment. They were classified into five groups as described by Moll and Wright, 
being entered into the group that best described the clinical manifestations. Clinicopathological characteristics recorded at enrolment 
were age at the time of examination, racial background, personal and family medical history, age and symptoms at the onset of PsA, 
pattern of joint involvement, joint pain, and the relationship between joint pain and the onset of PsA.
Results. Of the patients, 59.1% had a polyarticular presentation indistinguishable from rheumatoid arthritis, 19.0% had distal 
interphalangeal involvement, 9.1% had spondyloarthropathy, 11.9% had oligoarthritis and 0.9% had arthritis mutilans. The 
epidemiological trends (male/female ratio 1.45:1, mean age at onset of arthritis 50.2 (standard deviation 11.8) years, female 
preponderance in the polyarticular group and male preponderance in the spondyloarthropathy and oligoarticular groups) were 
similar to trends published elsewhere. A notable characteristic of our cohort was the complete absence of black South Africans with 
PsA.
Conclusions. The complete absence of black South Africans with PsA is interesting. We anticipate that our findings will prompt genetic 
studies to isolate both protective and susceptibility genes for further elucidating PsA.
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Assessment of patient and disease characteristics
Patients’ clinicopathological characteristics, determined at the 
time of initial examination, were recorded. These included age at 
the time of examination, racial group, personal and family medical 
history, age and symptoms at the onset of PsA, pattern of joint 
involvement, joint pain and the relationship between joint pain 
and the onset of PsA. Any extra-articular manifestations were 
also recorded. Peripheral joint involvement was assessed using 
the 68/66 tender/swollen joint count. The evaluation of axial 
involvement included the occiput-to-wall distance, tragus-to-wall 
distance and goniometric assessment of the range of movement 
of the cervical spine. Mobility of the lumbar spine was assessed 
based on a modified Schober test, fingertip-to-floor distance and 
lateral flexion of the lumbar spine. Thoracic spine movement 
was assessed based on chest expansion. The sacroiliac joints 
were examined using Patrick’s FABER (Flexion, ABduction, and 
External Rotation) test, anterior posterior pelvic pressure over 
the anterior superior iliac spine, lateral pelvic compression, direct 
pressure over the sacroiliac joints and Gaenslen’s test (Table 1).[11] 
Treatment was begun at enrolment, and treatment strategies were 
recorded.
At enrolment, a full blood count was done and the erythrocyte 
sedimentation rate (ESR, Westergren), C-reactive protein (CRP), 
urea and electrolytes, serum uric acid, serum lipids and plasma 
glucose concentration were measured. The presence of anti-
cyclic citrullinated peptide (anti-CCP) antibodies was detected 
using an enzyme-linked immunosorbent assay, and antinuclear 
antibodies (ANAs) were detected by immunofluorescence. HLA-
B27 typing was performed in all patients, and liver function tests 
were done.
Plain radiographs of the hands, feet, pelvis and lumbar spine were 
obtained on all patients at enrolment. The radiographs were read by 
one of several radiologists with an interest in inflammatory arthritis 
and were evaluated for erosions and new bone formation. The 
sacroiliac joints were assessed and described based on the modified 
New York criteria.[12]
At enrolment, patients were categorised into one of five clini-
cal groups according to the Moll and Wright PsA subtypes.[1] 
Categorisation was based on both clinical and radiographic findings.
Results
Overall patient characteristics
Of the 384 patients in the study, 157 were women and 227 were 
men (male/female ratio 1.45:1). Most patients were referred 
to the clinic by a general practitioner, family practitioner or 
dermatologist, and a small percentage of patients (5.1%) were 
self-referred. Two hundred and forty-seven of the patients were 
of Indian descent, 135 were of European descent, and 2 were of 
mixed descent. Ninety-three (24.2 %) of the patients had a family 
history of psoriasis or PsA. The mean age at the onset of psoriasis 
was 38.4 (standard deviation (SD) 9.3) years, and the mean age 
at the onset of arthritis was 50.2 (SD 11.8) years. In 341 patients 
(88.8%) the psoriasis preceded the arthritis. Six patients had nail 
changes without skin changes, and their disease was characterised 
by DIP involvement. Five patients had inflammatory arthritis with 
dactylitis and enthesopathy and a family history of psoriasis, but 
no current evidence of psoriasis. Five patients had uveitis as the 
only extra-articular manifestation, and 3 of these 5 patients were 
HLA-B27-positive. No other extra-articular manifestations were 
noted in our patient cohort.
Joint distribution
All five Moll and Wright PsA subtypes were represented in our study 
(Table 2), with polyarthritis, indistinguishable from rheumatoid 
arthritis, found most often (59.1% of the 352 patients in whom 
subtypes did not overlap). The next most common subtype was the 
DIP subtype (19.0%) followed by the oligoarticular type (11.9%); 
spondyloarthropathy accounted for 9.1% of the cases and arthritis 
mutilans for 0.9%.
Among the patients in the polyarticular PsA group, 81.7% (170/208) 
were found to have metacarpophalangeal (MCP) involvement, 
68.3% (142/208) radiocarpal involvement and 68.3% (142/208) 
metatarsophalangeal (MTP) involvement (Table 3). Among patients 
in the oligoarticular PsA group, the knees (52.4%) and ankles 
(35.7%) were most frequently involved. In nine patients in this 
group, asymmetrical oligoarticular involvement of the lower limbs 
was associated with sacroiliitis. Only three patients had severe 
arthritis mutilans. In all three, the arthritis mutilans involved digits 
of the upper and lower limbs. Female sex was predominant in the 
polyarthritis group (113/208 (54.3%) women v. 95/208 (45.7%) 
men) and male sex was predominant in the spondyloarthritis group 
(22/32 (68.7%) men v. 10/32 (31.3%) women) (Table 2). There was 
also a male preponderance in the oligoarticular group, with a male/
female ratio of 2.8:1. Fingernail changes, including pitting of the nails, 
onycholysis and nail dystrophy, were observed in 72.1% (277/384) of 
the patients.
Table 1. Joint assessments used
Peripheral Cervical Thoracic Lumbar Sacroiliac
68/66 count Occiput-to-wall distance Chest expansion Modified Schober test Patrick’s FABER test
Tragus-to-wall distance Fingertip-to-floor distance Anterior posterior pelvic pressure
Goniometric assessment Lateral flexion Lateral pelvic compression
Direct pressure over the sacroiliac joints
Gaenslen’s test
Table 2. Classification of the study patients (N=352) according 
to Moll and Wright[1] PsA subtypes*
PsA subtype Patients, n M/F ratio
Polyarticular 208 95/113 (1:1.2)
DIP 67 44/23 (1.9:1)
Oligoarticular 42 31/11 (2.8:1)
Spondylitis predominant 32 22/10 (2.2:1)
Arthritis mutilans 3 1/2 (1:2)
M/F = male/female.
*Thirty-two of the 384 patients had overlapping subtypes and were not included in any 
specific group.
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Laboratory data
ESR, CRP, RF and anti-CCP measurements at enrolment are shown 
in Table 4. An elevated ESR was noted in only 99/384 patients 
(25.8%). The ESR elevation was greater in the polyarticular group 
than in the spondyloarthropathy group (mean 46 mm/h v. 38 mm/h). 
However, CRP was elevated in 243 (63.3%) of patients, to a mean 
concentration of 15.3 mg/L (normal range 0 - 8). After 6 months of 
disease-modifying antirheumatic drug (DMARD) therapy, the mean 
CRP level dropped to 7.1 mg/L. Results of liver function tests were 
normal, with the exception of hyperglobulinaemia in all patients. 
Nineteen patients (4.9%) tested positive for RF and 15 (3.9%) for anti-
CCP antibodies. Six patients tested positive for ANAs; however, none 
of them fulfilled the American College of Rheumatology criteria for 
a diagnosis of systemic lupus erythematosus (SLE).
HLA-B27 positivity was noted in 57 patients (14.8% ). Twenty-
eight of these patients had axial involvement, and 29 patients with 
oligo- or polyarticular disease exhibited HLA-B27 positivity. Of 
the patients who were positive for HLA-B27, 35 (61.4%) were of 
European descent, only 22 (38.6%) being of Indian origin.
Radiological assessment
All patients underwent radiological examination of the hands, feet, 
sacroiliac joints and lumbar spine at enrolment. Sacroiliitis of grade 2 
or above was noted in 22 of the 32 patients with spondyloarthropathy 
(14 men v. 8 women). Five patients had syndesmophytes, which were 
asymmetrical and unilateral. The radiographic features of peripheral 
joint involvement included soft-tissue swelling, erosion, joint space 
narrowing, ankylosis and new bone formation.
Treatment
Treatment was assessed at 6 months. All the patients were DMARD 
naive at enrolment. Of the total of 384 patients, 256 (66.6%) received 
methotrexate monotherapy at an average dose of 17.5 mg/week 
(range 7.5 - 25). Disease activity remained low in these patients, with 
a mean simplified disease activity index of 7.6. Seventy-three patients 
(19.0%) were given a combination of methotrexate and sulfasalazine, 
and 45 (11.7%) triple therapy with methotrexate, sulfasalazine and 
leflunomide. Only 10 patients received biologicals, and none received 
hydroxychloroquine or chloroquine. Corticosteroids were only used 
intra-articularly for acute flare-ups.
Discussion
To the best of our knowledge, this is the first study to explore the clinical, 
laboratory and radiological characteristics of a fairly large cohort of SA 
PsA patients. Three hundred and eighty-four patients diagnosed with 
PsA were included, of whom 352 could be classified according to the 
Moll and Wright criteria.[1] The epidemiological findings in our study 
(male/female ratio 1.45:1, mean age at onset of arthritis 50.2 (SD 11.8) 
years, female preponderance in the polyarticular group and male 
preponderance in the spondyloarthropathy and oligoarticular groups) 
are similar to trends published elsewhere. [13] Other classification 
criteria have also been found to be similar when applied to an SA 
cohort.[14] One notable characteristic of our patient group was the 
complete absence of black South Africans with PsA. PMMH is a 
large regional hospital to the south of Durban and is the only referral 
rheumatology centre in this region. The catchment population is 
1.6 million (82.4% black Africans), and 92.3% of hospital outpatients 
are black Africans. At the rheumatology clinic, 63.5% of patients are 
black Africans presenting with various other rheumatological problems 
including rheumatoid arthritis, SLE, osteoarthritis and HIV-associated 
arthropathy.[15] The racial distribution needs to be explored further. 
Whether black Africans with PsA would also be lacking in a larger 
patient group remains to be determined, but it appears that psoriasis/
PsA may be absent in the black population. The reasons for this lack of 
susceptibility are not clear, but could be related to the low prevalence 
of HLA-B27 in this population. Psoriasis has been noted in the HIV-
positive black population.
In most of our patients, the psoriasis developed before the arthritis. 
The distribution of joint involvement observed in our cohort was 
similar to distributions published elsewhere.[13]
The reason for the limited use of biological therapy in our patient 
group was that PsA is not well covered by medical insurance in SA. 
Medical insurance in SA does not reimburse PsA patients for bio-
logical therapy.
Conclusions
This study of the epidemiological, clinical and radiological features 
of a fairly large cohort of SA patients with PsA yielded data similar 
to results for other populations. The complete absence of black South 
Africans with PsA in our cohort may be related to the low prevalence 
of HLA-B27 in this population. There may be yet-to-be-identified 
protective genes in this population group. We anticipate that our 
findings will prompt genetic studies to isolate both protective and 
susceptibility genes for further elucidating PsA.
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